For the first time, a study has confirmed that using the HIV-prevention pill can effectively thwart the virus in uninfected men by a significant amount, a finding that patient activists argue should spur public health officials to more aggressively push for wider access to the medicine.

By giving men the PrEP pill on a rapid and targeted basis, the HIV diagnosis rate fell by 25 percent in just one year, from 295 cases in the fall of 2016 to 221 cases the following year, according to the study, which was published in The Lancet HIV journal.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Cytodyn /Pro 140 Puts this Drug to SHAME. Whe have absolutely no SIDE EFFECTS. GILEAD SHOULD BUY US OUT. WE ALSO HAVE A CURE FOR VARIOUS CANCERS

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy